Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.
暂无分享,去创建一个
[1] T. Maniatis,et al. Multilevel Regulation of Gene Expression by MicroRNAs , 2008, Science.
[2] F. Holsboer,et al. Neuronal actions of glucocorticoids: Focus on depression , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[3] R. Finkel,et al. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy , 2008, Annals of neurology.
[4] M. Wood,et al. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] Johan T den Dunnen,et al. Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.
[6] N. Bresolin,et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. , 2007, Cell stem cell.
[7] Rolf Backofen,et al. Pre-mRNA Secondary Structures Influence Exon Recognition , 2007, PLoS genetics.
[8] I. Graham,et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. , 2007, Human gene therapy.
[9] G. van Ommen,et al. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. , 2007, RNA.
[10] Guey-Shin Wang,et al. Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.
[11] P. Iversen,et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] Christopher P. Bonin,et al. High-lysine corn generated by endosperm-specific suppression of lysine catabolism using RNAi. , 2007, Plant biotechnology journal.
[13] N. Corbi,et al. Utrophin Up-Regulation by an Artificial Transcription Factor in Transgenic Mice , 2007, PloS one.
[14] P. Iversen,et al. Bmc Molecular Biology Antisense Oligonucleotide Induced Exon Skipping and the Dystrophin Gene Transcript: Cocktails and Chemistries , 2022 .
[15] N. Bresolin,et al. Autologous Transplantation of Muscle-Derived CD133+ Stem Cells in Duchenne Muscle Patients , 2007, Cell transplantation.
[16] Meenal Patel,et al. PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.
[17] M. Stecker,et al. The sarcoglycan complex in Schwann cells and its role in myelin stability , 2007, Experimental Neurology.
[18] M. Stanton,et al. Cystic fibrosis mortality and survival in the UK: 1947–2003 , 2007, European Respiratory Journal.
[19] J. Chamberlain,et al. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. , 2007, Biochimica et biophysica acta.
[20] M. Schwartz,et al. Deletion of exon 16 of the dystrophin gene is not associated with disease , 2007, Human mutation.
[21] Christophe Béroud,et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.
[22] J. Rousseau,et al. Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] C. Bell,et al. Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy , 2007, Journal of Medical Genetics.
[24] S. Wilton,et al. The influence of antisense oligonucleotide length on dystrophin exon skipping. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] H. Deckmyn,et al. False positive results in chimeraplasty for von Willebrand Disease. , 2007, Thrombosis research.
[26] G. Schmitz. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide. , 2006, Current opinion in molecular therapeutics.
[27] S. Fortuni,et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors , 2006, Nature Medicine.
[28] G. van Ommen,et al. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[29] Michael Q. Zhang,et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. , 2006, Human molecular genetics.
[30] G. van Ommen,et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.
[31] Y. Takeshima,et al. Intravenous Infusion of an Antisense Oligonucleotide Results in Exon Skipping in Muscle Dystrophin mRNA of Duchenne Muscular Dystrophy , 2006, Pediatric Research.
[32] A. Musarò,et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Wilton,et al. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide , 2006, The journal of gene medicine.
[34] A. Rabinowitz,et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology , 2006, Nature Medicine.
[35] Thomas A Rando,et al. Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[36] T. Stockley,et al. Strategy for comprehensive molecular testing for Duchenne and Becker muscular dystrophies. , 2006, Genetic testing.
[37] G. van Ommen,et al. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. , 2005, Oligonucleotides.
[38] F. Rivier,et al. Mutation spectrum leading to an attenuated phenotype in dystrophinopathies , 2005, European Journal of Human Genetics.
[39] S. Wilton,et al. Terminal antisense oligonucleotide modifications can enhance induced exon skipping , 2005, Neuromuscular Disorders.
[40] Y. Takeshima,et al. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle , 2005, Brain and Development.
[41] J. Bourke,et al. The multidisciplinary management of Duchenne muscular dystrophy , 2005 .
[42] Thomas W Prior,et al. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. , 2005, The Journal of molecular diagnostics : JMD.
[43] P. Sharp,et al. Transcriptional silencing of a transgene by RNAi in the soma of C. elegans. , 2005, Genes & development.
[44] A. Rabinowitz,et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] Luis Garcia,et al. Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping , 2004, Science.
[46] Y. Takeshima,et al. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. , 2004, Human gene therapy.
[47] Y. Takeshima,et al. Chimeric RNA and 2'-O, 4'-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA. , 2004, Oligonucleotides.
[48] J. Mendell,et al. Three‐tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD) , 2004, Human mutation.
[49] D. Ittig,et al. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA. , 2004, Nucleic acids research.
[50] G. van Ommen,et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.
[51] S. Wilton,et al. Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle , 2003, FEBS letters.
[52] S. Wilton,et al. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. , 2003, Human molecular genetics.
[53] C. Mann,et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse , 2003, Nature Medicine.
[54] B. Cisneros,et al. Differential expression and subcellular distribution of dystrophin Dp71 isoforms during differentiation process , 2003, Neuroscience.
[55] T. Rando,et al. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping. , 2003, Human molecular genetics.
[56] F. Baas,et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. , 2003, Human molecular genetics.
[57] Christof von Kalle,et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.
[58] C. Mann,et al. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy , 2002, The journal of gene medicine.
[59] G. V. Ommen,et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy , 2002, Neuromuscular Disorders.
[60] A. Emery. Muscular dystrophy into the new millennium , 2002, Neuromuscular Disorders.
[61] T. Rando,et al. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. , 2002, Human gene therapy.
[62] A. Krainer,et al. Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.
[63] Andrew P. Weir,et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. , 2002, Physiological reviews.
[64] Y. Takeshima,et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient , 2001, Brain and Development.
[65] R. Mutani,et al. Late onset and very mild course of Xp21 Becker type muscular dystrophy. , 2001, Clinical neuropathology.
[66] F. Baas,et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. , 2001, Human molecular genetics.
[67] Y. Hamel,et al. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. , 2001, Human gene therapy.
[68] C. Mann,et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[69] J. T. Dunnen,et al. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family , 2000, European Journal of Human Genetics.
[70] R. Ross,et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. , 2000, Journal of applied physiology.
[71] N. Keep,et al. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. , 2000, Structure.
[72] F. Deist,et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.
[73] S. Wilton,et al. Massive Idiosyncratic Exon Skipping Corrects the Nonsense Mutation in Dystrophic Mouse Muscle and Produces Functional Revertant Fibers by Clonal Expansion , 2000, The Journal of cell biology.
[74] G. Schmajuk,et al. Antisense Oligonucleotides with Different Backbones , 1999, The Journal of Biological Chemistry.
[75] C. Langford,et al. Molecular analysis of a spontaneous dystrophin `knockout' dog , 1999, Neuromuscular Disorders.
[76] F. Muntoni,et al. X-linked dilated cardiomyopathy and the dystrophin gene , 1999, Neuromuscular Disorders.
[77] S. Agrawal,et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides , 1999, Neuromuscular Disorders.
[78] L. Morandi,et al. Development of muscle pathology in canine X-linked muscular dystrophy. I. Delayed postnatal maturation of affected and normal muscle as revealed by myosin isoform analysis and utrophin expression , 1999, Acta Neuropathologica.
[79] E. Bertini,et al. Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy , 1998, Neurology.
[80] J. Gillis,et al. Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse , 1998, Neuromuscular Disorders.
[81] M. Manoharan,et al. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. , 1998, Human molecular genetics.
[82] N. Laing,et al. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? , 1997, Neuromuscular Disorders.
[83] K. Campbell,et al. Transient expression of Dp140, a product of the Duchenne muscular dystrophy locus, during kidney tubulogenesis. , 1997, Developmental biology.
[84] Y. Takeshima,et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. , 1996, Biochemical and biophysical research communications.
[85] G. Danieli,et al. Duchenne phenotype with in‐frame deletion removing major portion of dystrophin rod: Threshold effect for deletion size? , 1996, Muscle & nerve.
[86] H. Nishio,et al. A Japanese boy with myalgia and cramps has a novel in‐frame deletion of the dystrophin gene , 1996, Neurology.
[87] L. Morandi,et al. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype , 1995, Journal of the Neurological Sciences.
[88] T. Helliwell,et al. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. , 1995, American journal of human genetics.
[89] K. Bushby,et al. Becker muscular dystrophy with onset after 60 years , 1994, Neurology.
[90] M. Passos-Bueno,et al. Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. , 1994, Human molecular genetics.
[91] K. Corrado,et al. Deletion analysis of the dystrophin‐actin binding domain , 1994, FEBS letters.
[92] N. Bresolin,et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. , 1994, Brain : a journal of neurology.
[93] N. Laing,et al. Identification of a point mutation and germinal mosaicism in a duchenne muscular dystrophy family , 1994, Human mutation.
[94] T. Vulliamy,et al. Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. , 1993, American journal of human genetics.
[95] A. Clarke,et al. Immunohistological evidence for second or somatic mutations as the underlying cause of dystrophin expression by isolated fibres in Xp21 muscular dystrophy of Duchenne-type severity , 1993, Journal of the Neurological Sciences.
[96] N. Laing,et al. Two distinct mutations in a single dystrophin gene: identification of an altered splice-site as the primary Becker muscular dystrophy mutation. , 1993, American journal of medical genetics.
[97] K. Bushby,et al. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. , 1993, Archives of disease in childhood.
[98] D. Bentley,et al. Infidelity in the structure of ectopic transcripts: A novel exon in lymphocyte dystrophin transcripts , 1993, Human mutation.
[99] G. Danieli,et al. Prevalence of dystrophin-positive fibers in 85 duchenne muscular dystrophy patients , 1992, Neuromuscular Disorders.
[100] R. Bartlett,et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. , 1992, Genomics.
[101] J. Mendell,et al. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. , 1992, American journal of human genetics.
[102] J. Shrager,et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy , 1991, Nature.
[103] H Sugita,et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.
[104] H. Nishio,et al. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe. , 1991, The Journal of clinical investigation.
[105] H. Nishio,et al. A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene. , 1990, Biochemical and biophysical research communications.
[106] L. Tsui,et al. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. , 1990, The New England journal of medicine.
[107] K. Davies,et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.
[108] I. Mcintosh,et al. FREQUENCY OF ΔF508 MUTATION ON CYSTIC FIBROSIS CHROMOSOMES IN UK , 1989, The Lancet.
[109] C. van Broeckhoven,et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. , 1989, American journal of human genetics.
[110] L. Kunkel,et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.
[111] K. Fischbeck,et al. Familial X‐linked myalgia and cramps , 1989, Neurology.
[112] C. van Broeckhoven,et al. Germinal mosaicism increases the recurrence risk for 'new' Duchenne muscular dystrophy mutations. , 1989, Journal of medical genetics.
[113] L. Kunkel,et al. Molecular genetics of Duchenne and Becker muscular dystrophy: emphasis on improved diagnosis. , 1989, Clinical chemistry.
[114] E A Barnard,et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.
[115] Doris M. Miller,et al. Muscular dystrophy in a litter of golden retriever dogs , 1988, Muscle & nerve.
[116] Jamel Chelly,et al. Transcription of the dystrophin gene in human muscle and non-muscle tissues , 1988, Nature.
[117] R. Waterston,et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. , 1988, The New England journal of medicine.
[118] A. Monaco,et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.
[119] M. Stephenson,et al. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[120] M. Stephenson,et al. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.